Hepatitis C virus (HCV) is the major cause of chronic liver disease worldwide. There is evidence that neutralizing an-ti-HCV antibodies may find potential applications in novel prophylactic and therapeutic strategies. This paper describes the very high neutralization activity and unique biological features of two broadly cross-reactive and cross-neutralizing anti-HCV human monoclonal IgG1 derived from human monoclonal recombinant Fab fragments.
|Number of pages||5|
|Publication status||Published - 2012|
- E2 glycoprotein
- Hepatits C virus (HCV)
- Neutralizing anti-HCV antibodies
ASJC Scopus subject areas
- Microbiology (medical)